Skip to main content
OpenTrials
Completed

NCT Number: NCT02608879

Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

The purpose of this study is to determine the effects of a novel oral care protocol on the severity and pain of oral mucositis in patients receiving radiation and/or chemotherapy for head and neck cancers. The secondary objectives are to characterize the microbiome associated with oral mucositis, measure salivary proinflammatory cytokines, and evaluate other clinical indicators of the intervention. Participants will be enrolled prior to beginning radiation and/or chemotherapy, and will be randomized to receive either the oral health protocol or standard of care oral hygiene.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Oral Mucositis Head and Neck Neoplasms Mouth Diseases Mouth Neoplasms Neoplasms Neoplasms by Site Oral Cancer Stomatitis Stomatognathic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Langone Medical Center

New York, 10016, United States

About this study

Oral mucositis (OM) is one of the most debilitating adverse effects in cancer patients treated with chemotherapy or radiation (RT). Currently, there are no effective therapies or prevention for mucositis, while several clinical studies have suggested that professional oral care could effectively reduce the severity of Radiation Therapy or chemotherapy-induced oral mucositis. Palliative treatment, rather than preventive or curative measures, remains the standard of care. Evidence-based guidelines do not provide consistent recommendations for the prevention, treatment and management of oral mucositis.

The investigators hypothesize that a monitored regimen of professional oral hygiene prevents harmful ecological shifts in the oral cavity, improve oral health and reduce the duration and severity of Oral Mucositis in cancer patients, consequently improving their overall quality of life during treatment. Moreover, the investigators hypothesize that the weekly oral hygiene regimen performed by an oral health professional is more effective in treating and preventing mucositis than current standard-of-care treatments.

The principal investigator of this project has developed a novel oral care regimen protocol for the treatment of oral mucositis. The "Oral Mucosa Deterging and Periodontal Debridement" (OMDP) protocol consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the debridement of the periodontium and deterging of the oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation. Co-adjuvant treatments such as intense fluoride treatments, oral hygiene instructions and palliative mouth-rinses are also part of the protocol. The hypothesis is that repeated professional prophylaxis of the oral cavity would protect the healthy oral tissue against infection and inflammation often associated with severe cases of mucositis, and consequently reduces mucositis incidence and duration.

Participants in this study would attend approximately 9 study visits over the course of 16-18 weeks, depending on their specific cancer treatment plan. Study participants will be randomized to receive either the oral health protocol, which they will receive on a weekly basis, or standard of care oral hygiene instructions and tooth brushing, preformed on a bi-weekly basis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patient aged 18 years or older;
  • Patients must sign an informed consent before data collection, screening, or initiation of study procedures;
  • Patients who are scheduled to undergo radiation or chemoradiation treatment for head/neck cancer;
  • Patients who have a minimum of 6 natural teeth at the time of enrollment.

Exclusion criteria

  • Female patients who are pregnant or lactating at the baseline/screening visit;
  • Patient participating in another biomedical/oral health research study that would interfere with participating in this study;
  • Patient deprived of freedom, under supervision or guardianship;
  • Patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons;
  • Immune compromised or other serious medical conditions, regardless of whether the condition is controlled or not;
  • Patient who requires pre-medication prior to dental treatment;
  • Any patient, in the opinion of the Investigator, who is unable or unlikely to comply fully with the study requirements or procedures for any reason (e.g. major surgical resection of intra-oral structures which would prevent oral care intervention, edentulous, severe periodontal disease, etc).

Treatment and study plan

Oral Mucosa Deterging and Periodontal Debridement (OMDP)

Procedure

OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.

Standard of Care Oral Hygiene Instructions

Procedure

Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.

Dental scaling, ultrasonic

Procedure

An ultrasonic dental scaler will be used to clean the teeth

Chlorhexidine

Other

Non-alcoholic chlorhexidine will be used as part of the OMDP protocol

Primary outcomes

  1. Oral Mucositis Severity - WHO Scale

    Time frame: End of Radiation Treatment (approximately week 7)

    OM severity will be assessed by the WHO Oral Mucositis Scale at each follow-up visit.

    The WHO Oral Mucositis Scale is a 5 point scale (0 to 4) with the following scoring system:

    0=None

    • Soreness with erythema
    • Erythema, ulcers, can eat solids
    • Ulcers, liquid diet only
    • Alimentation not possible

  2. Oral Mucositis Severity - NCI Scale

    Time frame: End of Radiation Treatment (approximately week 7)

    OM severity will be assessed by the NCI-CTCAE Scale (National Cancer Institute - Common Toxicity Criteria and Grading of Adverse Events) at each follow-up visit.

    The NCI-CTCAE is a 5 point scale (1-5) with the following grading system:

    • Erythema of the mucosa
    • Patchy ulcerations or pseudomembranes
    • Confluent ulcerations or pseudomembranes; bleeding with minor trauma
    • Tissue necrosis; significant spontaneous bleeding; life-threatening consequences
    • Death

Secondary outcomes

  1. Level of Oral Pain (FACES Scale)

    Time frame: End of Radiation Treatment (approximately week 7)

    The FACES Scale is a 6 point scale which ranges from 0-10 (and includes even numbers only). The scale is accompanied by illustrations of faces which represent each score. The subjects is shown the scale and asked to choose the face that best depicts the pain they are experiencing.

    0=No hurt 2=Hurts a little bit 4=Hurts a little more 6=Hurts even more 8=Hurts a whole lot 10-Hurts the worst you could imagine

  2. Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Right Side) From Baseline to Onset of Oral Mucositis

    Time frame: Baseline to Onset of Oral Mucositis

    The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.

    A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.

    For this data, the top five most abundant microbial species are presented.

  3. Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Left Side) From Baseline to Onset of Oral Mucositis

    Time frame: Baseline to Onset of Oral Mucositis

    The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.

    A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.

    For this data, the top five most abundant microbial species are presented.

  4. Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Right Side) From Baseline to Onset of Oral Mucositis

    Time frame: Baseline to Onset of Oral Mucositis

    The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.

    A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.

    For this data, the top five most abundant microbial species are presented.

  5. Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Left Side) From Baseline to Onset of Oral Mucositis

    Time frame: Baseline to Onset of Oral Mucositis

    The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.

    A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.

    For this data, the top five most abundant microbial species are presented.

  6. Change in the Level of Salivary Proinflammatory Cytokines From Baseline to 16 Weeks

    Time frame: Baseline and 16 weeks (final study visit)

    The level of salivary proinflammatory cytokines will be compared between the two groups at each follow-up visit.

  7. Change in Quality of Life as Measured by the Composite Score of the EORTC

    Time frame: Baseline to the peak of mucositis (approximately week 4)

    Quality of life will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) and Head & Neck module (EORTC-H&N) and compared between the two groups at each follow-up visit.

    There is not a single composite score for the entire questionnaire, but rather composite scores for each type of assessment (e.g. physical functioning, global health, swallowing, etc.). Possible scores range from 0-100. A lower score indicates low levels of that trait, which a higher score indicates high levels of that trait (e.g. a 100 for "physical functioning" indicates a high level of physical function).

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Acronym: OMDP

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Nov 20, 2015
Registry last updated
Aug 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.